Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
05 sept. 2024 07h00 HE
|
Ocugen
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
04 sept. 2024 07h46 HE
|
ANEW MEDICAL, INC.
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
03 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Fractyl Health to Participate in Upcoming September Investor Conferences
03 sept. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Participate in Upcoming September Investor Conferences
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology
30 août 2024 08h59 HE
|
SNS Insider pvt ltd
Pune, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Gene Therapy Market Size & Growth Overview: “According to SNS Insider, The Gene Therapy Market Size was valued at USD 9.2 Billion in 2023 and is...
CGT Research Outlook Technology Report 2024: Capacity and Capability Expansion for CDMOs, Technology Licensing Partnerships, Shift Towards CGT Development for Chronic Diseases
30 août 2024 06h46 HE
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "CGT Research Outlook and Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The report covers the...
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
28 août 2024 06h30 HE
|
Ocugen
MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes
27 août 2024 05h02 HE
|
Amarna Therapeutics
Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes Leiden, The Netherlands, 27th August 2024 - Amarna...
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
26 août 2024 07h02 HE
|
Ocugen
MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...